Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1975 1
1976 1
1977 2
1978 2
1979 2
1980 4
1981 3
1982 5
1983 8
1984 10
1985 6
1986 9
1987 5
1988 9
1989 15
1990 10
1991 8
1992 6
1993 6
1994 8
1995 10
1996 9
1997 6
1998 11
1999 11
2000 10
2001 8
2002 9
2003 16
2004 8
2005 16
2006 16
2007 21
2008 23
2009 23
2010 21
2011 27
2012 26
2013 38
2014 31
2015 37
2016 36
2017 25
2018 26
2019 39
2020 53
2021 51
2022 54
2023 53
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

781 results

Results by year

Filters applied: . Clear all
Page 1
Omacetaxine Mepesuccinate for Chronic Myeloid Leukemia.
Rosshandler Y, Shen AQ, Cortes J, Khoury HJ. Rosshandler Y, et al. Expert Rev Hematol. 2016 May;9(5):419-24. doi: 10.1586/17474086.2016.1151351. Epub 2016 Apr 21. Expert Rev Hematol. 2016. PMID: 26853281 Review.
Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option for a subset of patients with refractory chronic myeloid leukemia....
Omacetaxine mepesuccinate has distinct but manageable adverse events profile. Omacetaxine mepesuccinate is a treatment option …
Omacetaxine.
[No authors listed] [No authors listed] 2017 Jan 6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2017 Jan 6. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643365 Free Books & Documents. Review.
Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid leukemia that is resistant to tyrosine kinase receptor antagonists. Omacetaxine is associated with a low rate of serum enzyme elevation dur …
Omacetaxine is a semisynthetic cephataxine that acts as a protein translation inhibitor and is used to treated chronic myeloid leukem …
Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia.
Nazha A, Kantarjian H, Cortes J, Quintás-Cardama A. Nazha A, et al. Expert Opin Pharmacother. 2013 Oct;14(14):1977-86. doi: 10.1517/14656566.2013.821464. Epub 2013 Jul 23. Expert Opin Pharmacother. 2013. PMID: 23875628 Review.
INTRODUCTION: Omacetaxine mepesuccinate (formerly known as homoharringtonine [HHT]) is a natural alkaloid with significant anticancer activity partly through inhibition of protein synthesis and induction of apoptosis. ...The development of an oral formulation of …
INTRODUCTION: Omacetaxine mepesuccinate (formerly known as homoharringtonine [HHT]) is a natural alkaloid with significant ant …
Omacetaxine mepesuccinate in chronic myeloid leukemia.
Al Ustwani O, Griffiths EA, Wang ES, Wetzler M. Al Ustwani O, et al. Expert Opin Pharmacother. 2014 Nov;15(16):2397-405. doi: 10.1517/14656566.2014.964642. Expert Opin Pharmacother. 2014. PMID: 25301179 Review.
INTRODUCTION: Homoharringtonine (HHT) and other alkaloid esters were originally isolated from the Cephalotaxus evergreen tree and have been used in traditional Chinese medicine since the 1970s to treat a variety of malignancies. ...AREAS COVERED: In this review, we summari …
INTRODUCTION: Homoharringtonine (HHT) and other alkaloid esters were originally isolated from the Cephalotaxus evergreen tree and hav …
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment Resurrected.
Winer ES, DeAngelo DJ. Winer ES, et al. Oncol Ther. 2018 Jun;6(1):9-20. doi: 10.1007/s40487-018-0058-6. Epub 2018 Mar 15. Oncol Ther. 2018. PMID: 32700137 Free PMC article. Review.
The advent of tyrosine kinase inhibitors (TKIs) has led to marked improvements in responses and overall survival; however, there is still a subset of patients that are either resistant through a multitude of mechanisms or intolerant to standard TKI therapy. Omacetaxine mep …
The advent of tyrosine kinase inhibitors (TKIs) has led to marked improvements in responses and overall survival; however, there is still a …
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Chen Y, Li S. Chen Y, et al. Onco Targets Ther. 2014 Jan 31;7:177-86. doi: 10.2147/OTT.S41786. eCollection 2014. Onco Targets Ther. 2014. PMID: 24516334 Free PMC article. Review.
In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesu …
In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acqu …
Omacetaxine as an anticancer therapeutic: what is old is new again.
Wetzler M, Segal D. Wetzler M, et al. Curr Pharm Des. 2011;17(1):59-64. doi: 10.2174/138161211795049778. Curr Pharm Des. 2011. PMID: 21294709 Review.
Omacetaxine mepesuccinate was originally identified more than 35 years ago and initial studies in chronic myeloid leukemia (CML) showed promising activity. ...However, the introduction of imatinib and related tyrosine kinase inhibitors (TKIs) abated the clinical developmen …
Omacetaxine mepesuccinate was originally identified more than 35 years ago and initial studies in chronic myeloid leukemia (CML) show …
Omacetaxine for treatment-resistant or treatment-intolerant adult chronic myeloid leukemia.
Chung C. Chung C. Am J Health Syst Pharm. 2014 Feb 15;71(4):279-88. doi: 10.2146/ajhp130506. Am J Health Syst Pharm. 2014. PMID: 24481153 Review.
Symptom improvement or improved overall survival in omacetaxine-treated patients has not been demonstrated. In clinical trials to date, the most common grade 1-4 adverse reactions included thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, and asthenia. ...C …
Symptom improvement or improved overall survival in omacetaxine-treated patients has not been demonstrated. In clinical trials to dat …
Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma.
Li L, Halpert G, Lerner MG, Hu H, Dimitrion P, Weiss MJ, He J, Philosophe B, Burkhart R, Burns WR, Wesson RN, MacGregor Cameron A, Wolfgang CL, Georgiades C, Kawamoto S, Azad NS, Yarchoan M, Meltzer SJ, Oshima K, Ensign LM, Bader JS, Selaru FM. Li L, et al. JCI Insight. 2021 Jun 22;6(12):e138197. doi: 10.1172/jci.insight.138197. JCI Insight. 2021. PMID: 34003798 Free PMC article.
Next, omacetaxine was tested against a larger cohort of 40 human HCC PDOs. ...Clinical trials could be considered to evaluate omacetaxine in patients with HCC....
Next, omacetaxine was tested against a larger cohort of 40 human HCC PDOs. ...Clinical trials could be considered to evaluate omac …
Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Narayanan V, Gutman JA, Pollyea DA, Jimeno A. Narayanan V, et al. Drugs Today (Barc). 2013 Jul;49(7):447-56. doi: 10.1358/dot.2013.49.6.1980495. Drugs Today (Barc). 2013. PMID: 23914353 Review.
Omacetaxine mepesuccinate is a protein synthesis inhibitor that causes apoptosis of chronic myeloid leukemia cells without binding to the BCR-ABL tyrosine kinase that is implicated in the pathogenesis of this disease. ...This review will focus on the preclinical pharmacolo …
Omacetaxine mepesuccinate is a protein synthesis inhibitor that causes apoptosis of chronic myeloid leukemia cells without binding to …
781 results

Searches related to "omacetaxine"